Bulk Manufacturer of Controlled Substances Application: Curia Missouri, Inc., 77109 [2023-24615]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 215 / Wednesday, November 8, 2023 / Notices
Controlled
substance
Nabilone .........................
Phenylacetone ................
Codeine ..........................
Dihydrocodeine ...............
Oxycodone .....................
Hydromorphone ..............
Hydrocodone ..................
Morphine .........................
Oripavine ........................
Thebaine .........................
Opium extracts ...............
Opium fluid extract .........
Opium, tincture ...............
Opium, powdered ...........
Opium, granulated ..........
Oxymorphone .................
Noroxymorphone ............
Tapentadol ......................
Drug
code
Schedule
7379
8501
9050
9120
9143
9150
9193
9300
9330
9333
9610
9620
9630
9639
9640
9652
9668
9780
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances as an Active Pharmaceutical
Ingredient for supply to its customers.
In reference to drug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–24613 Filed 11–7–23; 8:45 am]
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on August 3, 2023, Curia
Missouri Inc., 2460 West Bennett Street,
Springfield, Missouri 65807–1229,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled
substance
Gamma Hydroxybutyric
Acid.
Amphetamine .................
Lisdexamfetamine ..........
Methylphenidate .............
Phenylacetone ................
Tapentadol ......................
Drug
code
Schedule
2010
I
1100
1205
1724
8501
9780
II
II
II
II
II
BILLING CODE P
The company plans to bulk
manufacture the listed controlled
substances for internal use
intermediates or for sale to its
customers. No other activities for these
drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1291]
Bulk Manufacturer of Controlled
Substances Application: Curia
Missouri, Inc.
Claude Redd,
Acting Deputy Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
[FR Doc. 2023–24615 Filed 11–7–23; 8:45 am]
Curia Missouri Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 8, 2024. Such
persons may also file a written request
for a hearing on the application on or
before January 8, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
DEPARTMENT OF LABOR
AGENCY:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:54 Nov 07, 2023
Jkt 262001
BILLING CODE P
Employee Benefits Security
Administration
220th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of Meeting
Pursuant to the authority contained in
section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 220th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans (also
known as the ERISA Advisory Council)
will be held on December 11–12, 2023.
On Monday, December 11, 2023, the
meeting will begin at 1:00 p.m. and end
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
77109
at approximately 4:30 p.m. (ET). On
Tuesday, December 12, 2023, the
meeting will begin at 8:30 a.m. and end
at approximately 3:00 p.m. (ET), with a
break for lunch.
The meeting will take place at the
U.S. Department of Labor, 200
Constitution Avenue NW, Washington,
DC 20210 in Room 6, C5320. The
meeting will also be accessible via
videoconference and some participants,
as well as members of the public, may
elect to attend virtually. Instructions for
public videoconference access will be
available on the ERISA Advisory
Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council
approximately one week prior to the
meeting.
The purpose of the open meeting is
for Advisory Council members to
finalize their observations and
recommendations on the issues they
studied in 2023, present their
observations and recommendations to
the Department of Labor, and receive an
update from leadership of the Employee
Benefits Security Administration
(EBSA).
The issues studied by the ERISA
Advisory Council in 2023 are: (1) LongTerm Disability Benefits and Mental
Health Disparity, and (2) Recordkeeping
in the Electronic Age. Descriptions of
these topics are available on the ERISA
Advisory Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council.
Organizations or members of the
public wishing to submit a written
statement may do so on or before
Monday, December 4, 2023, to Christine
Donahue, Executive Secretary, ERISA
Advisory Council. Statements should be
transmitted electronically as an email
attachment in text or pdf format to
donahue.christine@dol.gov. Statements
transmitted electronically that are
included in the body of the email will
not be accepted. Relevant statements
received on or before Monday,
December 4, 2023, will be included in
the record of the meeting and made
available through the EBSA Public
Disclosure Room. No deletions,
modifications, or redactions will be
made to the statements received as they
are public records. Warning: Do not
include any personally identifiable or
confidential business information that
you do not want publicly disclosed.
Individuals or representatives of
organizations interested in addressing
the ERISA Advisory Council at the
public meeting must submit a written
request to the Executive Secretary on or
before Monday, December 4, 2023, via
email to donahue.christine@dol.gov.
E:\FR\FM\08NON1.SGM
08NON1
]]>Agencies
[Federal Register Volume 88, Number 215 (Wednesday, November 8, 2023)]
[Notices]
[Page 77109]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24615]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1291]
Bulk Manufacturer of Controlled Substances Application: Curia
Missouri, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Curia Missouri Inc. has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
January 8, 2024. Such persons may also file a written request for a
hearing on the application on or before January 8, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on August 3, 2023, Curia Missouri Inc., 2460 West
Bennett Street, Springfield, Missouri 65807-1229, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
Amphetamine............................ 1100 II
Lisdexamfetamine....................... 1205 II
Methylphenidate........................ 1724 II
Phenylacetone.......................... 8501 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for internal use intermediates or for sale to its customers.
No other activities for these drug codes are authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-24615 Filed 11-7-23; 8:45 am]
BILLING CODE P
